Liminal BioSciences: Surges after FDA approves genetic disorder drug

Liminal BioSciences

04/06/2021 21:54

** U.S.-listed shares of Canadian drugmaker  LMNL.O  surge
~51% to $6.10 in extended trading
    ** Says U.S. FDA has approved Ryplazim for treatment of
plasminogen deficiency  urn:newsml:reuters.com:*:nCNWJ95mha
    ** Plasminogen deficiency is a genetic disorder associated
with inflammed growths on the mucous membranes
    ** Ryplazim was previously granted 'orphan drug' and 'rare
pediatric disease' designations by FDA for treatment of
congenital plasminogen deficiency
    ** U.S. stock down ~4.3% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))